Pancreatic cancer strikes quickly and mercilessly. Luciano Pavarotti, Ruth Bader Ginsburg, Sven-Göran Eriksson, Johannes Brost. The names are many, the fates tragic. The diagnosis is a death sentence. But now there is hope.
Pancreatic cancer is one of the most aggressive and difficult-to-treat forms of cancer, with a very low five-year survival rate of only 10-12%. This means that most patients who are diagnosed face a very bleak prognosis, regardless of when the disease is detected.
Unlike breast cancer, for example, where early detection gives a very good prognosis, research has long had great difficulty in developing effective treatments for pancreatic cancer.
Many famous people, such as Luciano Pavarotti and Ruth Bader Ginsburg, have suffered and died from this disease. Despite the bleak figures, today there is a new hope. In Södertälje, in Astra’s old premises, the Swedish biotech company Anocca is developing a ground-breaking immunotherapy that could give future patients a new chance of survival. At the heart of Anocca’s work is the development of advanced therapies based on the body’s own T cells. By manipulating these specialized immune cells, they are trained to recognize and attack cancer cells with extreme precision, without harming healthy cells.
The research taking place today in Södertälje enables the development of customized T-cell receptors that can identify mutations deep inside cells, not just surface structures. By analyzing genetic information from the patient’s blood and tumor tissue, treatments can be individually tailored, opening the door to much more targeted and effective therapies.
The vision is to build a library of T-cell receptors covering multiple patient groups and cancer types, making this tailored immunotherapy available to many more patients than today. Anocca’s technology is already protected by over 50 approved patents, with more on the way.
International experts in the field, such as Dr. Michael Kalos and Professor Christoph Springfeld, believe that Anocca is one of the leaders in TCR-based cell therapy and has the potential to revolutionize the treatment of solid tumors, just as cell therapy has already transformed the treatment of blood cancers. With powerful technology platforms, strong expertise and large-scale manufacturing capabilities, Anocca can become a key player in the fight against one of the deadliest cancers.
